FindTrial
Sign In

Comparsion of levetiracetam and sodium valproate mono therapy in childhood epilepsy

Open label randomised comparison of levetiracetam and sodium valproate monotherapy in childhood epilepsy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/11/010605
Enrollment
100
Registered
2017-11-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- newly diagnosed childhood epilepsy

Interventions

None listed

Sponsors

NONE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed focal motor or generalised epilepsy

Exclusion criteria

Exclusion criteria: 1.Children who are on anti epileptic for more than 15 days 2.Children with congenital anomalies or developmental delay or microcephaly 3.Acute head trauma or post traumatic epilepsy

Design outcomes

Primary

MeasureTime frame
Treatment will be considered successful if there is no repeat seizure activity for 6 monthsTimepoint: Treatment will be considered successful if there is no repeat seizure activity for 6 months—

Secondary

MeasureTime frame
1.Side effect profile of the patients in each group 2.Achievement of therapeutic drug levels at steady state and 6 months 3.Time to first seizure after steady state of drugTimepoint: 6 months—

Countries

India

Contacts

Public ContactDr ANju Aggarwal

University college of medical sciences

swatibh1312@gmail.com9582026730

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026